Introduction
death
EVENTS, CYTOTOXICITY, REFRACTORY MULTIPLE MYELOMA
Substantial advances have been made in the management of patients with relapsed and/or refractory multiple myeloma (RRMM) with the adoption of proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) within treatment regimens. This patient population is increasing worldwide due to improved life expectancy and other demographic changes [Addition of a monoclonal antibody, such as an anti-CD38 antibody, to a PI (e.g., bortezomib, carfilzomib [K]) or an IMiD (e.g., pomalidomide, lenalidomide) plus low-dose dexamethasone [d], within triplet regimens, has led to further significant improvements in clinical outcomes for patients with RRMM [The anti-CD38 monoclonal antibody isatuximab (Isa) exerts anti-myeloma activity through several mechanisms of action including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and direct induction of apoptotic cell death [Isa was further approved in combination with carfilzomib and low-dose dexamethasone (Isa-Kd) in the United States for RRMM patients after 1–3 prior lines of therapy, in the European Union and other countries for patients with relapsed MM who have received ≥1 prior therapy, and in Japan for patients with RRMM [To evaluate longer term outcomes with Isa-Kd vs Kd in patients with relapsed MM, we conducted a follow-up, prespecified analysis of the IKEMA study population at 159 PFS events. Here, we report updated study results on PFS, CR rate, MRD negativity rate, MRD negativity and CR rate, in the intent-to-treat population, as well as updated safety findings.